EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Machine Learning‐Based Predictive Modeling Maximizes the Efficacy of mTOR /p53 Co‐Targeting Therapy Against AML

Jingmei Li iD, Emi Sugimoto, Keita Yamamoto, Yutong Dai, Wenyu Zhang, Yu-Hsuan Chang iD, Jakushin Nakahara, Tomohiro Yabushita, Toshio Kitamura, Sung-Joon Park, Kenta Nakai, Susumu Goyama iD

Cancer Science · 2025

DOI: 10.1111/cas.70170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Jingmei Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, TOR Serine-Threonine Kinases, Tumor Suppressor Protein p53, Machine Learning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, The Japanese Society of Hematology, The NOVARTIS Foundation Japan for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although mTOR signaling plays a key role in acute myeloid leukemia (AML), mTOR inhibitors have shown limited efficacy against AML in clinical trials. In this study, we found that the anti‐leukemic effect of mTOR inhibition was mediated in part through the TP53 pathway. mTOR inhibition by rapamycin and TP53 activation by DS‐5272 collaboratively induced the downregulation of MYC and MCL1 partly through miR‐34a, thereby inducing cell cycle arrest and apoptosis in AML cells. Joint non‐negative matrix factorization (JNMF) and statistical regression analysis using public AML databases revealed that monocytic AMLs with distinctive gene expression profiles were highly sensitive to mTOR inhibition, leading to the generation of an 11‐gene score (Rapa‐11) to predict the rapamycin sensitivity of each monocytic AML. Consistent with our in silico prediction, mouse AML cells expressing MLL‐AF9, the monocytic AML with a low Rapa‐11 score, were highly sensitive to rapamycin, whereas those expressing RUNX1‐ETO or SETBP1/ASXL1 mutations were not. Co‐treatment with rapamycin and DS‐5272 had a dramatic in vivo effect on MLL‐AF9‐driven AML, curing 85% of the leukemic mice. Thus, machine learning‐based predictive approaches identified monocytic AML with wild‐type TP53 and low Rapa‐11 score as a rapamycin‐sensitive AML subtype and an ideal target for mTOR/p53 co‐targeting therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTOR Serine-Threonine KinasesTumor Suppressor Protein p53Machine LearningMTOR InhibitorsHumansAnimalsMiceSirolimusCell Line, TumorApoptosisSignal TransductionXenograft Model Antitumor Assays

Stichwörter der Autor:innen

TP53acute myeloid leukemiajoint non‐negative matrix factorizationmTORmachine learning

Substanzen

TOR Serine-Threonine KinasesTumor Suppressor Protein p53SirolimusMTOR protein, humanMTOR InhibitorsTP53 protein, human

Autor:innen und Institutionen

  • Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Hyogo, Japan.
  • Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Jingmei Li, Yu-Hsuan Chang, Susumu Goyama

Förderung

  • Japan Agency for Medical Research and Development
  • The Japanese Society of Hematology
  • The NOVARTIS Foundation Japan for the Promotion of Science
  • Japan Society for the Promotion of Science
  • The Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Uehara Memorial Foundation
  • Graduate School of Frontier Sciences, University of Tokyo
  • Japanese Society of Hematology

Zitieren

APA

Li, J., Sugimoto, E., Yamamoto, K., Dai, Y., Zhang, W., Chang, Y. H., Nakahara, J., Yabushita, T., Kitamura, T., Park, S. J., Nakai, K., & Goyama, S. (2025). Machine Learning‐Based Predictive Modeling Maximizes the Efficacy of mTOR /p53 Co‐Targeting Therapy Against AML. Cancer Science. https://doi.org/10.1111/cas.70170

Vancouver

Li J, Sugimoto E, Yamamoto K, Dai Y, Zhang W, Chang YH, et al. Machine Learning‐Based Predictive Modeling Maximizes the Efficacy of mTOR /p53 Co‐Targeting Therapy Against AML. Cancer Science. 2025. doi:10.1111/cas.70170

BibTeX
@article{Li2025,
  author = {Li, Jingmei and Sugimoto, Emi and Yamamoto, Keita and Dai, Yutong and Zhang, Wenyu and Chang, Yu-Hsuan and Nakahara, Jakushin and Yabushita, Tomohiro and Kitamura, Toshio and Park, Sung-Joon and Nakai, Kenta and Goyama, Susumu},
  title = {Machine Learning‐Based Predictive Modeling Maximizes the Efficacy of mTOR /p53 Co‐Targeting Therapy Against AML},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70170}
}
Kostenlos starten →